IRS2 and leukemia: The participation of IRS1 and IRS2 in oncogenic pathways (namely, the BCR-ABL1 68,69, JAK2V167F76 and IRS1/β-catenin 89 pathways) described by our research group corroborates the participation of these proteins in the malignant phenotype of leukemias and suggests that these protein targets are druggable (Figure 3).